Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Events Timeline

(ET)

2026-01-12

07:20:00

Oruka Therapeutics Reports Positive Interim Data from ORKA-002 Phase 1 Trial

2025-11-12 (ET)

2025-11-12

17:01:53

Oruka Therapeutics announces Q3 earnings per share of 55 cents, surpassing consensus estimate of 52 cents.

News

8.0

01-09NASDAQ.COM

Five Below Options Volume Hits 7,969 Contracts, 71.5% of Daily Average

1.0

01-06Globenewswire

Oruka to Present Novel Biologics at 44th Annual J.P. Morgan Healthcare Conference

4.5

2025-12-31NASDAQ.COM

Sprott Silver Miners ETF Declines 2.3% with Americas Gold and Vizsla Silver Underperforming

4.0

2025-11-13Benzinga

Gilead Sciences Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Thursday

6.0

2025-11-13Benzinga

AutoZone Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Thursday

4.0

2025-11-13Benzinga

BTIG Reaffirms Buy Rating for Oruka Therapeutics and Increases Price Target to $63

10 Analyst Rating

Wall Street analysts forecast ORKA stock price to rise

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

40.00

Averages

51.67

High

75.00

Current: 0.000

Low

40.00

Averages

51.67

High

75.00

Clear Street

Kaveri Pohlman

Buy

maintain

$71

AI Analysis

2026-02-04

Reason

Clear Street

Kaveri Pohlman

Price Target

$71

AI Analysis

2026-02-04

maintain

Buy

Reason

Clear Street analyst Kaveri Pohlman believes AbbVie's (ABBV) plan to bring an extended half-life anti-IL-23 mAb into the clinic this year further validates Oruka Therapeutics' (ORKA) strategy. Together with Rapt Therapeutics' (RAPT) recent $2.2B takeout by GSK (GSK) for a half-life-extended Xolair analog, these moves reinforce the view that convenience-oriented drugs are becoming preferred development bets in I&I-and potentially even in oncology, Clear Street argues. The firm further states that Oruka's IL-23 lead and ORKA-002 rights provide structural edge, making competition less of a concern, Clear Street reiterates a Buy rating on Oruka with a price target of $71.

UBS

Buy

initiated

$50

2026-01-07

Reason

UBS

Price Target

$50

2026-01-07

initiated

Buy

Reason

UBS initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $50 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ORKA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Oruka Therapeutics Inc (ORKA.O) is -10.68, compared to its 5-year average forward P/E of -6.99. For a more detailed relative valuation and DCF analysis to assess Oruka Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.99

Current PE

-10.68

Overvalued PE

-4.39

Undervalued PE

-9.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding ORKA

Cormorant Asset Management, LP

Paradigm Biocapital Advisors LP

Deep Track Capital, LP

Perceptive Advisors LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Oruka Therapeutics Inc (ORKA) stock price today?

The current price of ORKA is 33.69 USD — it has decreased -2.09

What is Oruka Therapeutics Inc (ORKA)'s business?

What is the price predicton of ORKA Stock?

Wall Street analysts forecast ORKA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORKA is51.67 USD with a low forecast of 40.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Oruka Therapeutics Inc (ORKA)'s revenue for the last quarter?

Oruka Therapeutics Inc revenue for the last quarter amounts to -34.10M USD, increased 15.81

What is Oruka Therapeutics Inc (ORKA)'s earnings per share (EPS) for the last quarter?

Oruka Therapeutics Inc. EPS for the last quarter amounts to -21701000.00 USD, decreased -38.05

How many employees does Oruka Therapeutics Inc (ORKA). have?

Oruka Therapeutics Inc (ORKA) has 28 emplpoyees as of March 03 2026.

What is Oruka Therapeutics Inc (ORKA) market cap?

Today ORKA has the market capitalization of 1.63B USD.

ORKA Overview

ORKA Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding ORKA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Oruka Therapeutics Inc (ORKA) stock price today?

What is Oruka Therapeutics Inc (ORKA)'s business?

What is the price predicton of ORKA Stock?

What is Oruka Therapeutics Inc (ORKA)'s revenue for the last quarter?

What is Oruka Therapeutics Inc (ORKA)'s earnings per share (EPS) for the last quarter?

How many employees does Oruka Therapeutics Inc (ORKA). have?

What is Oruka Therapeutics Inc (ORKA) market cap?